NASDAQ · AYTU

AYTU BioPharma, Inc.

$2.16 $0.00 (+0.00%) 1D Market open
Charting by TradingView

Key Metrics

$23.18M
Market cap
—
P/E · TTM
$56.60M
Revenue · TTM
−$34.06M
Net income
EPS · TTM $-3.41
Dividend yield —
Free cash flow $1.64M
Beta · 1Y 0.92
EBITDA · TTM −$29.57M
Gross margin 64.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 18
    The stock moved +9.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 18
  • Feb 4
    The stock moved -10.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$23.18M
Enterprise value$7.87M
Shares outstanding10.7M
52-wk range$1.65 – $3.07
Avg volume · 20D117.1K
Net cash $15.31M
Book value / share$3.52
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About AYTU BioPharma, Inc.
IPO dateFeb 15, 2008
Employees83

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S0.41
P/FCF14.10
EV/EBITDA—
EV/Sales0.14
Graham №—

Profitability

Gross 64.8%
Operating -59.5%
Net -60.2%
FCF 2.9%
ROE / ROIC -108.4% · -172.0%

Financial Health

Current ratio1.12
Quick ratio1.00
Debt / equity0.32
Debt / EBITDA -0.39
Net cash $15.31M
Working capital$7.35M

Cash Flow · TTM

Operating CF $1.68M
Capex −$34.00K
Free cash flow $1.64M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings